Back to results
US 2026/0217722 A1Published application
Inhibitors of bruton's tyrosine kinase
AssigneePharmacyclics, Inc.
InventorsJoseph J. Buggy, Wei Chen, Lee Honigberg, David J. Loury, Zhengying Pan, Erik J. Verner
Life of this patent
Estimating the term…
Abstract
Described herein are irreversible kinase inhibitor compounds, methods for synthesizing such irreversible inhibitors, and methods for using such irreversible inhibitors in the treatment of diseases. Further described herein are methods, assays and systems for determining an appropriate irreversible inhibitor of a protein, including a kinase.
Claims20
1-100. (canceled)
A compound of Formula (B2) having the structure:
- wherein:
- Y is alkylene or substituted alkylene, or a 4-, 5-, or 6-membered cycloalkylene ring;
- each Ra is independently H, halogen, —CF3, —CN, —NO2, OH, NH2, -La-(substituted or unsubstituted alkyl), -La-(substituted or unsubstituted alkenyl), -La-(substituted or unsubstituted heteroaryl), or -La-(substituted or unsubstituted aryl), wherein La is a bond, O, S, —S(═O), —S(═O)2, NH, C(O), CH2, —NHC(O)O, —NHC(O), or —C(O)NH;
- G is
- wherein,
- R6, R7 and R8 are independently selected from H, lower alkyl or substituted lower alkyl, lower heteroalkyl or substituted lower heteroalkyl, substituted or unsubstituted lower cycloalkyl, and substituted or unsubstituted lower heterocycloalkyl;
- R12 is H or lower alkyl;
- or
- Y and R12 taken together form a 4-, 5-, or 6-membered heterocyclic ring;
- or
- or a pharmaceutically acceptable salt thereof.
8 more elements
Dependencies are inferred from the claim text.